Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Jie He, Jianming Ying et al.|Journal of Thoracic Oncology|2020Cited by 415
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesW J Guo, Shugeng Gao, Liang Zhao et al.|European Journal of Cancer|2025Cited by 2